|
|
Post by cedafuntennis on Dec 15, 2021 10:58:15 GMT -5
And how many people (doctors included) do the bare minimum just to get by? Afrezza is not SOC yet so many doctors who should know because "it is their job" have never heard of it. It is our interest to push it not the doctors, as the doctors are happy with the SOC as it is; patients be damned.
|
|
|
|
Post by stevil on Dec 15, 2021 11:14:30 GMT -5
I've tried to give perspective on this in the past but I'll try again. The great majority of doctors are far from lazy, careless, lack compassion, etc. They're human beings with families and other obligations outside of medicine who already work long hours and are taxed with excessive documentation and paperwork.
There are plenty of other factors to derail and distract them from "the practice of medicine". That is not an excuse, it's a fact.
Add to this the ever increasing drug formulations and I would say it is impossible (no hyperbole) to stay on top of all new medications. When drug companies simply change the formulation of a compound from tablet to liquid to inhaled or add a longer-acting molecule to the same basic active ingredient, it's not hard to get a new formulation of an already existing drug.
I'm still in residency and I've already stopped paying attention to "the latest and greatest" simply because the pharmaceutical industry is out of control. They will do whatever they can to make more money. Changing an already existing compound is the cheapest way to do so as the bulk of the research and development has already been done. There is very little innovation these days to justify the cost of new medications.
It is up to the manufacturer to differentiate their product, not the physician's. Without evidence to prove why their product is superior to the existing standard of care, do not expect physicians to do clinical trials of their own unless personally motivated for some other reason. So when a physician sees "human insulin" - which has existed in other formulations since the 70s- do not be surprised if there is slow uptake in the context of poor clinical trials proving superiority. The standard of care is such for a reason. It has been tried and true and has yielded the greatest and most beneficial results over a patient population.
I'll add that it will be even harder for Afrezza to become the sole standard of care for diabetes once SGLT-2s and GLP-1s go off patent as their benefits extend beyond diabetes into the cardiac and renal spaces. The only way I see Afrezza being used exclusively is if the diabetes is caught early and effectively treated to prevent further comorbid conditions. Once those other comorbidities arise, depending on glucose control, Afrezza may be the odd man out if additional glucose control is not needed with other therapies. SGLT-2s are now or soon becoming the standard of care for heart failure and chronic kidney disease patients, regardless of diabetes status as the use has shown great benefit for these other conditions. GLP-1s are soon to follow.
|
|
|
|
Post by mango on Dec 15, 2021 12:05:30 GMT -5
The most under recognized piece of information was Receptor Life Sciences initiating Phase 1 Cannabidiol Technosphere. This is a huge milestone. I cannot wait for the read out early next year. Congrats!
In regards to SGLT-2s and GLP-1s, neither do very much for the mealtime spike, as evidenced by CGMs. Additionally, neither address the underlying defect with T2D—Afrezza does. Afrezza restores the first phase insulin response and post prandial glucose homeostasis—Extraordinary!
Further, SGLT-2s are associated with potentially horrific adverse events, such as the life threatening medical condition it induced called Fournier's gangrene (as well as unpleasant side effects). GLP-1s are associated with pancreatic cancer and amputations. These are both terrible choices for PWDs. Best to stick with the safest and most effective treatment, which is Afrezza.
The ADA’s Standards of Care have proven to be a treat to failure.
|
|
|
|
Post by sportsrancho on Dec 15, 2021 13:30:12 GMT -5
In answer to Peppy…..I’m wondering what is driving people to the website…. Outside of Instagram etc. is it in medical magazines….
|
|
|
|
Post by mango on Dec 15, 2021 14:06:39 GMT -5
In answer to Peppy…..I’m wondering what is driving people to the website…. Outside of Instagram etc. is it in medical magazines…. Nate Pile has posted pictures of Afrezza being advertised in Diabetes Care. The HCP was probably listed on those ads somewhere |
|
|
|
Post by porkini on Dec 15, 2021 14:28:20 GMT -5
How are they getting the providers to the website? Many times on the afrezza page that comes up, at the top of the page is a link for health care providers. afrezza.comthere it is on the top of the page, healthcare professional site. Providers know there are links to the professional sites on the medication website. Heck, I knew it.  I have not looked at the websites for awhile now. They have a much better look to them and seem more user friendly to me now. A couple things I do not recall from before, or at the very least these have been improved: 1. HCP page now has a prominent "Request a Rep" link at top ( afrezzahcp.com/afrezzaassist/#) *If you click the link, it provides a form for the practitioner to fill out and then: Have an Afrezza Field Representative deliver the following to me: Product Information Free Samples Free Inhaler Demonstration Kits Free FEV1 Kits Free BluHale PRO Inhalation Training Device 2. The "Find a Doctor" page is now map based and pinpoints by type of practitioner ( afrezza.com/find-a-doctor/) *If you right-click on the map, there are some other ways you can toggle (like Heat Map) to see the map differently. |
|
|
|
Post by sayhey24 on Dec 20, 2021 14:10:51 GMT -5
I've tried to give perspective on this in the past but I'll try again. The great majority of doctors are far from lazy, careless, lack compassion, etc. They're human beings with families and other obligations outside of medicine who already work long hours and are taxed with excessive documentation and paperwork. There are plenty of other factors to derail and distract them from "the practice of medicine". That is not an excuse, it's a fact. Add to this the ever increasing drug formulations and I would say it is impossible (no hyperbole) to stay on top of all new medications. When drug companies simply change the formulation of a compound from tablet to liquid to inhaled or add a longer-acting molecule to the same basic active ingredient, it's not hard to get a new formulation of an already existing drug. I'm still in residency and I've already stopped paying attention to "the latest and greatest" simply because the pharmaceutical industry is out of control. They will do whatever they can to make more money. Changing an already existing compound is the cheapest way to do so as the bulk of the research and development has already been done. There is very little innovation these days to justify the cost of new medications. It is up to the manufacturer to differentiate their product, not the physician's. Without evidence to prove why their product is superior to the existing standard of care, do not expect physicians to do clinical trials of their own unless personally motivated for some other reason. So when a physician sees "human insulin" - which has existed in other formulations since the 70s- do not be surprised if there is slow uptake in the context of poor clinical trials proving superiority. The standard of care is such for a reason. It has been tried and true and has yielded the greatest and most beneficial results over a patient population. I'll add that it will be even harder for Afrezza to become the sole standard of care for diabetes once SGLT-2s and GLP-1s go off patent as their benefits extend beyond diabetes into the cardiac and renal spaces. The only way I see Afrezza being used exclusively is if the diabetes is caught early and effectively treated to prevent further comorbid conditions. Once those other comorbidities arise, depending on glucose control, Afrezza may be the odd man out if additional glucose control is not needed with other therapies. SGLT-2s are now or soon becoming the standard of care for heart failure and chronic kidney disease patients, regardless of diabetes status as the use has shown great benefit for these other conditions. GLP-1s are soon to follow. Maybe once the SGLT-2s and GLP-1s go off patent afrezza will become the standard of care. BP will stop having interest once there is no longer big money with them. There is only one way cells are going to get the glucose they need and that is insulin. SGLT2 and GLP-1 are not a replacement for insulin. They simplify mask the fact that the body is not making enough insulin for its needs. I doubt when it comes to cardiac health pissing out sugar and keeping BG at 170+ can compete head to head with afrezza which can keep a PWD in a near normal range and below 140. It would be nice for one of these SGLT2 BPs to fund a head to head study against a properly dosed afrezza. For cardiac health not to mention retinopathy I would bet the farm on afrezza. |
|
|
|
Post by brentie on Jan 5, 2022 7:48:51 GMT -5
|
|
|
|
Post by sportsrancho on Jan 5, 2022 8:21:10 GMT -5
Classless
|
|
